dc.contributor.author
Ahsan, Dalia Melina
dc.contributor.author
Altrichter, Sabine
dc.contributor.author
Gutsche, Annika
dc.contributor.author
Bernstein, Jonathan A.
dc.contributor.author
Altunergil, Tatjana
dc.contributor.author
Brockstaedt, Maxi
dc.contributor.author
Maurer, Marcus
dc.contributor.author
Weller, Karsten
dc.contributor.author
Terhorst‐Molawi, Dorothea
dc.date.accessioned
2025-04-03T12:36:44Z
dc.date.available
2025-04-03T12:36:44Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/47135
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-46853
dc.description.abstract
Background
Cold urticaria (ColdU) is a form of inducible urticaria where cold induces wheals and/or angioedema. The burden of disease is high and linked to trigger thresholds, exposure, and avoidance. There are presently no validated patient-reported outcome measures (PROMs) to assess and monitor disease activity. Our objective was to develop a disease-specific activity score for ColdU that is easy to administer and evaluate.
Methods
A Cold Urticaria Activity Score (ColdUAS) questionnaire was developed, directed by PROM developing guidelines. After the generation of a conceptional framework, the item generation phase included the literature research on ColdU signs and symptoms and on comparable tools for similar diseases and 47 ColdU patient interviews. Subsequently, an impact analysis for content validity was performed. The final selection of items underwent expert review for face validity and cognitive debriefing.
Results
The ColdUAS, a self-administered questionnaire for the prospective assessment of disease activity in patients with ColdU, consists of 4 items: 1. the frequency and severity of the signs (wheals and/or angioedema), 2. the frequency and severity of the symptoms (e.g., itch and burn), 3. the exposure to specific triggers, and 4. the avoidance of these triggers. The recall period for each item is the last 24 h.
Conclusions
The ColdUAS is the first disease-specific PROM to assess ColdU disease activity. It may help to better assess patients' disease status in routine clinical practice as well as in clinical trials. Anchor-based approaches are currently used to validate the ColdUAS.
en
dc.rights.uri
https://creativecommons.org/licenses/by-nc/4.0/
dc.subject
chronic inducible urticaria
en
dc.subject
cold urticaria
en
dc.subject
disease activity
en
dc.subject
patient-reported outcome measures
en
dc.subject
urticaria activity score
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Development of the Cold Urticaria Activity Score
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1111/all.15310
dcterms.bibliographicCitation.journaltitle
Allergy
dcterms.bibliographicCitation.number
8
dcterms.bibliographicCitation.originalpublishername
Wiley
dcterms.bibliographicCitation.pagestart
2509
dcterms.bibliographicCitation.pageend
2519
dcterms.bibliographicCitation.volume
77
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
DEAL Wiley
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
35403217
dcterms.isPartOf.issn
0105-4538
dcterms.isPartOf.eissn
1398-9995